Pharma's game of hiring economists to say any law they don't like will crater innovation is nothing new. Throwback to '77 spon-con in the American Economics Review where economists fret over the impact of the FDA's '62 requirement that companies show that drugs actually work.

Today is giving me all the feels 🥹. Climate & Community Project turns into Climate & Community INSTITUTE! I'm so proud of what we have built over 4 yrs. We are more than a short-term project-- we want to be an institutional home for the climate left. climateandcommunity.org

Just learned that Rio Tinto, one of the world's largest mining conglomerates, starts quarterly earnings calls with a land acknowledgement

Our new report with Nuffield Council on Bioethics assesses the benefits, risks and role of AI-powered genomic health prediction. While there could be healthcare benefits, there are also significant privacy, discrimination and structural risks to people and society. adalovelaceinstitute.org/report/predict…

The NHS should not widely roll-out AI-powered genomic health prediction yet, we say in a new report with Ada Lovelace Institute. The report assesses the benefits, risks & role of AI-powered genomic health prediction. Find out more: bit.ly/3Xob90o #NHS #Health #genomics

🚨NEW: An industrial strategy & democratic corporate governance are NEEDED for AI to serve public good rather than private gain. Our latest briefing by Eleanor Shearer introduces a new series of work challenging Big Tech's concentrated market power. 🧵 common-wealth.org/publications/t…

For years, policy people have talked (written op eds) about health systems of the future in which insight provided by genomic testing helps people avoid getting ill in the first place. (1/8)

Look, I talk a lot about compute, but we're seeing many nations now force-feeding it without considering the bigger picture—some call it "sovereign AI." The idea that AI ambitions can be solved just by giving NVIDIA more money is misguided. We need strategies beyond compute. 1/

🎉📢 I'm on the tenure track job market! 👋✨ I study how people building “AI” think about the downstream harms their work makes possible, and the epistemic and political economic systems which shape their thoughts, and our future.

In which Chris Hayes and I discuss the architectural form of the public enterprise, fractured agency and the state in electricity markets, and whether we need to overthrow capital tout court before we can decarbonize. Thanks to The Break Down and Adrienne Buller

Bored by convos that don't get past "Public pharma, is it good or bad?" Come IRL or zoom in to a T1International #insulin4all LPE Blog Yale GHJP deep dive into the politics, practice, and future of public pharma. We have a great line-up of speakers (and snacks!) Sept 17 - 6pm

File under: AI as a solution-in-search-of-its-problem. We're seeing more direct calls to mobilize global (+public!) capital not just to keep pace with its logics of endless scaling (cue: bloomberg.com/news/articles/…) But also to then find ways to make this worthwhile (=profitable) 🤪

We often hear that “all economists agree rent controls don’t work”. But is this actually true? My new long-read for @futureeconscot looks at the evidence – and finds the reality is far more nuanced than is often claimed. Some key points 🧵 futureeconomy.scot/posts/57-can-r…

Launching a new LPE book series with Cambridge University Press. Send us your proposals! lpeproject.org/events/call-fo…

If Novo Nordisk and Eli Lilly and Company will not lower GLP-1 prices to reasonable levels, there are alternatives. Bernie Sanders announced today that he has been in talks with generic manufacturers who confirmed they would sell #Ozempic for $100/month - 1/10th the current price. 1/🧵